March 2, 2021 – 3D Medicines Inc. announced the appointment of Shen Xiao, M.D., Ph.D., as Chief Strategy Officer. He would be responsible for tasks including strategic innovation, competitive positioning and business model establishment for the company, he would provide support for the Chief Executive Officer on strategy planning and execution, and be in charge of the Regulatory Affairs Department. Shen Xiao, M.D., Ph.D., would report to John Gong, M.D., Ph.D., Chairman and Chief Executive Officer of 3D Medicines.
Shen Xiao, M.D., Ph.D., Chief Strategy Officer of 3D Medicines
Shen Xiao, M.D., Ph.D., has rich and comprehensive experience in new drug review. During his approximately 20-year work in U.S. Food and Drug Administration (FDA), he has been responsible for hundreds of reviews for new drugs at the development stage, and has been in charge of the New Drug Application (NDA) or Biologics License Application (BLA) of a dozen new drugs as a clinical reviewer or a multi-discipline review team leader. Also, he has taken charge of or participated in the drafting or formulation of several FDA guidances on new drug development, and he has taken part in discussions with the European Medicines Agency (EMA) and Health Canada about International Council on Harmonization (ICH) guidelines and the administration standards for certain drugs. He graduated from Qingdao Medical College of Qingdao University and Shanghai Jiao Tong University School of Medicine (formerly Shanghai No.2 Medical University), received his Ph.D. from West Virginia University and completed his postdoctoral research in Johns Hopkins University and the University of North Carolina. Besides, he worked for Nanjing General Hospital of Nanjing Military Command, Nephropathy Research Center of People’s Liberation Army (PLA), and has received awards including Third Class National S&T Progress Award and Second Class S&T Progress Award of the PLA.
John Gong, M.D., Ph.D., Chairman and Chief Executive Officer of 3D Medicines, commented: “I am glad to have Shen Xiao, M.D., Ph.D., joining us. Up to now, the NDA of Envafolimab, the world's first subcutaneous PD-L1 antibody innovative drug co-developed by the company, has been granted Priority Review by National Medical Products Administration (NMPA); the IND approval from the NMPA of 3D011, the first self-developed drug, has been received; and the construction of our R&D and Manufacturing Center has recently started in Xuzhou. It is exactly the critical time when 3D Medicines’ endeavors to achieve the goal of a pharmaceutical company integrating research, production, and marketing are in full swing; so a clearer strategic orientation, round-the-clock monitoring of market trends and timely strategic adjustments are urgently needed. I believe that the rich experience and professional background of Shen Xiao, M.D., Ph.D., will provide powerful drive and a directional assurance for the continuous rapid development of 3D Medicines.”
Shen Xiao, M.D., Ph.D., Chief Strategy Officer of 3D Medicines, commented: “I am extremely impressed and excited by the forward-looking product layout, the rapid development, the powerful momentum, the patient-oriented value, and the excellent and efficient staff of 3D Medicines. It is a great honor for me to join 3D Medicines as Chief Strategy Officer and to participate and witness the beneficial cause of developing innovative drugs for cancer patients worldwide. I am convinced that, with the leadership of John Gong, M.D., Ph.D., and the efforts of everyone here at 3D Medicines, we will achieve our vision of ‘helping people with cancer live longer and better’. ”
About 3D Medicines
3D Medicines, Inc. is a clinical-stage biopharmaceutical company with a mission to help people with cancer live longer and better. Envisioning a future when cancer is managed as a chronic disease, 3D Medicines focuses on the development of differentiated next-generation immuno-oncology drugs, helping cancer patients live with prolonged survival time and a better quality of life. 3D Medicines has established a pipeline with both next-generation biological macromolecule and chemotherapeutic small-molecule drugs, as well as a professional team capable of global development, registration and commercialization operation.
For more information, please visit: www.3d-medicines.com
The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development.